JORDAN BAILEY: Open Payments
NPI 1750507372 · POWHATAN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,033 in 103 payments from 24 companies in 2025. Trend: 2023 $2,035 · 2024 $1,689 · 2025 $2,033
Food & beverage: $2,033
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $295 |
| AstraZeneca Pharmaceuticals LP | 14 | $284 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $161 |
| Amgen Inc. | 13 | $141 |
| Eisai Inc. | 1 | $125 |
| Vanda Pharmaceuticals Inc. | 4 | $111 |
| Lilly USA, LLC | 6 | $104 |
| TMS NeuroHealth Centers Inc. | 1 | $97 |
| Novo Nordisk Inc | 5 | $88 |
| PFIZER INC. | 4 | $85 |
Products named: CAPLYTA, QULIPTA, Leqembi, VRAYLAR, OTEZLA, REXULTI, MOUNJARO, TMS NeuroHealth Centers Inc..
Industry payments across VA — which companies pay providers there.
